Back to GetFilings.com



Table of Contents
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
Form 10-Q
 
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the Quarterly Period Ended: June 30, 2002
 
Commission File Number: 0-22333
 
Nanophase Technologies Corporation
(Exact name of registrant as specified in its charter)
 
Delaware
(State or other jurisdiction of
incorporation or organization)
 
36-3687863
(I.R.S. Employer
Identification No.)
 
1319 Marquette Drive, Romeoville, Illinois 60446
(Address of principal executive offices, and zip code)
 
Registrant’s telephone number, including area code: (630) 771-6708
 

 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes   X      No
 
As of August 13, 2002, there were outstanding 15,106,032 shares of common stock, par value $.01, of the registrant.
 


Table of Contents
NANOPHASE TECHNOLOGIES CORPORATION
 
QUARTER ENDED JUNE 30, 2002
 
INDEX
 
    
Page

  
3
  
3
  
3
  
4
  
5
  
6
  
8
  
11
  
12
  
12
  
12
  
12
  
13
  
13
  
14
 

2


Table of Contents
PART I—FINANCIAL INFORMATION
 
Item 1.    Financial Statements
 
NANOPHASE TECHNOLOGIES CORPORATION
 
BALANCE SHEETS
(Unaudited)
 
    
June 30,
2002

    
December 31,
2001

 
ASSETS
                 
Current assets:
                 
Cash and cash equivalents
  
$
530,965
 
  
$
582,579
 
Investments
  
 
10,175,857
 
  
 
6,842,956
 
Trade accounts receivable, less allowance for doubtful accounts of $25,000 at June 30, 2002 and December 31, 2001
  
 
1,043,149
 
  
 
1,112,952
 
Other receivable, net
  
 
74,006
 
  
 
67,449
 
Inventories, net
  
 
776,815
 
  
 
956,268
 
Prepaid expenses and other current assets
  
 
295,429
 
  
 
381,696
 
    


  


Total current assets
  
 
12,896,221
 
  
 
9,943,900
 
Equipment and leasehold improvements, net
  
 
9,090,981
 
  
 
8,914,745
 
Other assets, net
  
 
349,596
 
  
 
325,743
 
    


  


    
$
22,336,798
 
  
$
19,184,388
 
    


  


LIABILITIES AND STOCKHOLDERS’ EQUITY
                 
Current liabilities:
                 
Current portion of long-term debt
  
$
629,854
 
  
$
714,135
 
Current portion of capital lease obligations
  
 
59,238
 
  
 
48,352
 
Accounts payable
  
 
584,959
 
  
 
1,233,466
 
Accrued expenses
  
 
1,223,670
 
  
 
732,427
 
    


  


Total current liabilities
  
 
2,497,721
 
  
 
2,728,380
 
    


  


Long-term debt, less current maturities
  
 
553,812
 
  
 
758,490
 
Long-term portion of capital lease obligations, less current maturities
  
 
66,970
 
  
 
53,900
 
    


  


    
 
620,782
 
  
 
812,390
 
    


  


Contingent liabilities
  
 
—  
 
  
 
—  
 
Stockholders’ equity:
                 
Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding
  
 
—  
 
  
 
—  
 
Common stock, $.01 par value, 25,000,000 shares authorized; 15,106,032 and 13,705,931 shares issued and outstanding at June 30, 2002 and December 31, 2001, respectively
  
 
151,060
 
  
 
137,059
 
Additional paid-in capital
  
 
56,568,815
 
  
 
50,260,747
 
Accumulated deficit
  
 
(37,501,580
)
  
 
(34,754,188
)
    


  


Total stockholders’ equity
  
 
19,218,295
 
  
 
15,643,618
 
    


  


    
$
22,336,798
 
  
$
19,184,388
 
    


  


 
See Notes to Financial Statements.
 

3


Table of Contents
NANOPHASE TECHNOLOGIES CORPORATION
 
STATEMENTS OF OPERATIONS
(Unaudited)
 
    
Three months ended June 30,

    
Six months ended June 30,

 
    
2002

    
2001

    
2002

    
2001

 
Revenue:
                                   
Product revenue
  
$
1,516,197
 
  
$
957,314
 
  
$
2,829,773
 
  
$
1,937,489
 
Other revenue
  
 
145,649
 
  
 
92,065
 
  
 
239,755
 
  
 
183,815
 
    


  


  


  


Total revenue
  
 
1,661,846
 
  
 
1,049,379
 
  
 
3,069,528
 
  
 
2,121,304
 
    


  


  


  


Operating expense:
                                   
Cost of revenue
  
 
1,401,696
 
  
 
1,006,749
 
  
 
2,696,720
 
  
 
1,857,122
 
Research and development expense
  
 
480,042
 
  
 
362,519
 
  
 
1,003,726
 
  
 
800,189
 
Selling, general and administrative expense
  
 
1,006,104
 
  
 
1,090,995
 
  
 
2,091,319
 
  
 
2,226,949
 
    


  


  


  


Total operating expense
  
 
2,887,842
 
  
 
2,460,263
 
  
 
5,791,765
 
  
 
4,884,260
 
    


  


  


  


Loss from operations
  
 
(1,225,996
)
  
 
(1,410,884
)
  
 
(2,722,237
)
  
 
(2,762,956
)
Interest income
  
 
33,041
 
  
 
165,436
 
  
 
61,177
 
  
 
416,616
 
Interest expense
  
 
(28,792
)
  
 
(8,272
)
  
 
(56,282
)
  
 
(17,664
)
Other, net
  
 
(951
)
  
 
(3,000
)
  
 
(50
)
  
 
(12,000
)
    


  


  


  


Loss before provision for income taxes
  
 
(1,222,698
)
  
 
(1,256,720
)
  
 
(2,717,392
)
  
 
(2,376,004
)
Provisions for income taxes
  
 
(30,000
)
  
 
(30,000
)
  
 
(30,000
)
  
 
(30,000
)
    


  


  


  


Net loss
  
$
(1,252,698
)
  
$
(1,286,720
)
  
$
(2,747,392
)
  
$
(2,406,004
)
    


  


  


  


Net loss per share—basic and diluted
  
$
(0.09
)
  
$
(0.09
)
  
$
(0.20
)
  
$
(0.18
)
    


  


  


  


Weighted average number of common shares outstanding
  
 
14,232,786
 
  
 
13,643,771
 
  
 
13,980,694
 
  
 
13,628,562
 
    


  


  


  


 
 
See Notes to Financial Statements.
 

4


Table of Contents
 
NANOPHASE TECHNOLOGIES CORPORATION
 
STATEMENTS OF CASH FLOWS
(Unaudited)
 
    
Six months ended June 30,

 
    
2002

    
2001

 
Operating activities:
                 
Net loss
  
$
(2,747,392
)
  
$
(2,406,004
)
Adjustment to reconcile net loss to net cash (used in) operating activities:
        
Depreciation and amortization
  
 
569,170
 
  
 
379,755
 
Allowance for excess inventory quantities
  
 
25,019
 
  
 
(12,172
)
Provision for asset write-down
  
 
—  
 
  
 
14,086
 
Changes in assets and liabilities related to operations:
                 
Trade accounts receivable
  
 
69,803
 
  
 
696,788
 
Other receivable
  
 
(6,557
)
  
 
51,352
 
Inventories
  
 
154,434
 
  
 
(1,129,513
)
Prepaid expenses and other assets
  
 
54,783
 
  
 
25,072
 
Accounts payable
  
 
62,261
 
  
 
758,945
 
Accrued liabilities
  
 
491,243
 
  
 
3,189
 
    


  


Net cash (used in) operating activities
  
 
(1,327,236
)
  
 
(1,618,502
)
Investing activities:
                 
Acquisition of equipment and leasehold improvements
  
 
(573,964
)
  
 
(3,821,301
)
Purchases of held-to-maturity investments
  
 
(55,698,953
)
  
 
(36,035,911
)
Maturities of held-to maturity investments
  
 
52,366,052
 
  
 
41,083,299
 
    


  


Net cash (used in) provided by investing activities
  
 
(3,906,865
)
  
 
1,226,087
 
Financing activities:
                 
Principal payment on debt obligations, including capital leases
  
 
(305,758
)
  
 
(153,259
)
Proceeds from borrowings
  
 
—  
 
  
 
782,333
 
Proceeds from sale of common stock, net, and exercise of stock options
  
 
6,322,069
 
  
 
285,370
 
Payments of accounts payable incurred for the purchase of equipment and leasehold improvements
  
 
(833,824
)
  
 
—  
 
    


  


Net cash provided by financing activities
  
 
5,182,487
 
  
 
914,444
 
    


  


(Decrease) increase in cash and cash equivalents
  
 
(51,614
)
  
 
522,029
 
Cash and cash equivalents at beginning of period
  
 
582,579
 
  
 
473,036
 
    


  


Cash and cash equivalents at end of period
  
$
530,965
 
  
$
995,065